Kim D. Blickenstaff Joins Tandem Diabetes Care as President & CEO
Tandem Diabetes Care, Inc., a privately held company, today announced that Kim D. Blickenstaff has joined the organization as president, chief executive officer and a member of the board of directors.
"We are delighted to have Kim on-board as the CEO of Tandem Diabetes Care. He has significant experience in successfully developing early-stage health care companies and he is the perfect fit for Tandem," said Dick Allen, Chairman of the Board of Directors, "We have made tremendous research and development advancements in the past year, and Kim brings us unique talents and strengths that will enhance our ability to introduce novel medical devices to the diabetes market."
Blickenstaff has more than 30 years of healthcare experience in finance, marketing management, sales and strategic planning. Most recently he was chairman, chief executive officer and co-founder of Biosite Incorporated, a medical diagnostic company that was acquired by Inverness Medical Innovations for $1.8 billion in June 2007. Throughout his career, Blickenstaff held various finance, operations, research management, sales management, strategic planning and marketing positions with Hybritech Incorporated and Baxter Healthcare. He has been active in the medical device and diagnostics industry over the last 12 years, serving on the board of directors for innovative, young healthcare companies. He holds a Masters of Business Administration from Loyola University Chicago's Graduate School of Business and a BA from Loyola University, Chicago.
Dedicated to advancing the management of diabetes, Tandem Diabetes Care, Inc. is an early-stage company using novel technology in the development of a medical device for insulin administration. Tandem is based in San Diego, Calif.